A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Name: A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Published: 2017
License: Public Domain

Astellas Pharma Global Development, Inc. · 2017

ClinicalTrials.gov · Datasets · License: Public Domain · 2017

Open Source ↗

acute-myeloid-leukemia

acute myeloid leukemia (aml), acute myeloid leukemia with fms-like tyrosine kinase (flt3) / internal tandem duplication (itd) mutation, acute myeloid leukemia, first complete remission, gilteritinib, flt3/itd, aml, asp2215, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Related documents